A clinical laboratory's economics are the opposite of an imaging center's: not one expensive study at a time but thousands of inexpensive results a day, each with a reimbursement set by a fee schedule that falls on a statutory cycle, a coverage rule that decides whether the payer will pay at all, and a cost structure where the reagent agreement hides the analyzer's capital cost in the price of every test. Laboratories report revenue per accession and volume per day; the margin lives in contribution per test by payer, which most independent laboratories have never computed.
What is net revenue per test, and how do coverage rules change it?
Reimbursement by test is set, not negotiated, for most of the volume. The Medicare clinical laboratory fee schedule, updated on a statutory cycle that has cut rates for many high-volume tests; state Medicaid schedules below it; commercial contracts typically expressed as a percentage of the Medicare schedule; client billing — where a physician practice or facility is billed directly at a negotiated price and bills the payer itself — at rates the laboratory sets; and self-pay at the laboratory's list.
Coverage and medical-necessity edits decide whether a test is paid. Payers restrict many tests to specific diagnosis codes and frequencies; a test ordered without a covered diagnosis denies, and the laboratory has already incurred the reagent and labor; the denial rate by test and by ordering source is the laboratory's revenue-cycle number — an ordering practice that sends a panel with the wrong diagnosis on a third of orders is sending the laboratory write-offs.
Net revenue per test by payer, from remittances. Cash collected over tests reported, by test and payer, over a trailing period — net of coverage denials, bundling edits that pay a panel at a single rate, and timely-filing losses; the number by test is usually a third or more below the schedule rate for the tests with coverage restrictions.
What does a test actually cost?
Reagent cost per reportable result. The reagent agreement's price per test — often under a reagent-rental arrangement where the analyzer is provided at no separate charge and the reagent price carries its capital cost — plus calibrators, controls, and the reagent consumed by repeats, quality control runs, and failed results; the cost per reportable result is the cost per result that reached a patient's chart, which is 10 to 25 percent higher than the cost per test performed.
The analyzer's capital cost, unbundled. A reagent-rental agreement that prices a test at US$2.40 may be carrying US$0.70 of analyzer financing and service inside it; the laboratory computes the capital component from the agreement's minimum-volume commitment and term, so it knows what it would pay for reagents alone and what it is paying for the machine — and so it can compare a purchase with a reagent-only contract.
Labor by phase. Pre-analytical — accessioning, specimen processing, phlebotomy where the laboratory provides it; analytical — technologist time by analyzer and test family; post-analytical — review, reporting, critical-value calls; allocated per test on time studies, because a test that runs on an automated chemistry line costs minutes of technologist time per hundred results while a manual microbiology culture costs minutes per result.
Allocated cost per test. Laboratory director oversight, quality and proficiency programs, certification and inspection, information systems and interfaces, courier and logistics for specimen pickup, billing with its coverage-edit burden, occupancy, and administration.
How is the in-house versus send-out decision made?
Test by test, on contribution. For each test: net revenue by payer, in-house cost per reportable result at the laboratory's actual volume (where volume drives the reagent price and the labor efficiency), and the reference laboratory's send-out price plus the laboratory's handling cost; a test with low volume and expensive reagent minimums costs more in-house than sent out; a test with high volume and a simple analyzer platform is a margin line in-house.
The volume threshold. For each candidate test, the volume at which in-house cost per result falls below the send-out price — because reagent agreements have minimums and analyzer capacity has a fixed component; below the threshold, send it out; above it, bring it in; and the threshold is recomputed when the fee schedule or the reagent price changes.
Turnaround and client service are in the decision. A send-out test with a three-day turnaround may lose the ordering practice to a laboratory that runs it in-house; the model carries the client-retention value of turnaround where it is material.
Why does the test menu need an annual review?
Reimbursement falls on a schedule. Fee-schedule cuts phase in by test; a panel that was profitable three years ago can be below cost today with no change in the laboratory's operations; the menu review re-runs contribution by test at current rates.
Volume shifts and reagent terms change. A client lost or won changes the volume that drives reagent pricing and labor efficiency; a reagent agreement renewal is a negotiation the laboratory should enter with its volume and its alternatives modeled.
The review's outputs. Tests to keep, reprice for client-bill accounts, bring in-house, send out, or discontinue; reagent agreements to renegotiate; and the client accounts whose test mix and denial rate make them unprofitable — because a laboratory's client list is its payer mix.
What does the client-account view add?
Client billing accounts are contracts. A physician practice or facility billed directly at negotiated per-test prices is a customer whose contribution is its price less cost per result, with its order volume, its mix, and — where the laboratory bills the payer on the account's behalf — its denial rate; accounts below cost are repriced or exited; accounts with high denial rates get diagnosis-coding support or a surcharge.
Courier and logistics by route. Specimen pickup routes have a cost per stop; a low-volume account on a long route can cost more in courier time than it earns; routing and pickup frequency are account-level economics.
Why is this CFO work?
Net revenue per test requires remittance data read by test, payer, and denial reason; cost per reportable result requires reagent agreements unbundled and labor time-studied by phase; the send-out decision is a volume-threshold model; the menu review is an annual re-run at current rates; and the client-account view is the laboratory's payer file. The laboratory director owns quality, methods, and compliance; the CFO owns the economics of the result.
Worked example
An independent clinical laboratory serving 140 physician practices and two facilities, US$11.6 million revenue, 1.9 million reportable results a year, three reagent-rental agreements.
| Test family | Share of results | Net revenue / result | Cost / reportable result | Contribution / result | Denial rate | Verdict |
|---|---|---|---|---|---|---|
| Basic and comprehensive metabolic panels | 31% | US$9.10 | US$5.80 | US$3.30 | 4% | Keep; renegotiate reagent minimums |
| Complete blood counts | 22% | US$6.40 | US$3.90 | US$2.50 | 3% | Keep |
| Lipid panels | 11% | US$8.20 | US$5.10 | US$3.10 | 9% (frequency edits) | Keep; coding support to top 10 ordering practices |
| Vitamin D | 9% | US$14.60 | US$19.40 | −US$4.80 | 31% (medical-necessity) | Largest loss; coverage-edit gate and client education, or send out |
| Thyroid panels | 8% | US$17.90 | US$11.20 | US$6.70 | 7% | Keep |
| Urine drug screens (client-billed) | 7% | US$21.00 | US$12.60 | US$8.40 | — | Keep; reprice two accounts below cost |
| Low-volume specialty tests (in-house) | 4% | US$38.00 | US$61.00 | −US$23.00 | 12% | Send out (reference price US$29 + US$4 handling) |
| Molecular (send-out) | 3% | US$96.00 | US$88.00 (reference + handling) | US$8.00 | 6% | Keep as send-out; bring in-house above 4,000/yr |
Illustrative figures for a hypothetical organization; not a client's data.
The laboratory's fourth-largest line by volume — vitamin D — was losing US$4.80 on every result because a third of orders arrived without a covered diagnosis and were written off after the reagent was consumed; nobody had computed it because revenue per accession looked fine. The plan: a coverage-edit gate at accessioning with a call-back to the ordering practice before the test runs; coding support for the ten practices generating most of the denials; the specialty tests moved to send-out (US$190,000 a year of in-house loss removed); reagent-rental agreements unbundled and renegotiated on volume at renewal (the chemistry agreement's analyzer component was US$0.68 per test against a purchase alternative at US$0.41); two client-bill accounts repriced; and an annual menu review set against the fee-schedule calendar. Modeled contribution improvement: about US$610,000 on the same volume.